Corbus Pharmaceuticals Holdings Future Growth

Future criteria checks 2/6

Corbus Pharmaceuticals Holdings is forecast to grow earnings and revenue by 4.7% and 76.7% per annum respectively while EPS is expected to grow by 20.5% per annum.

Key information

4.7%

Earnings growth rate

20.49%

EPS growth rate

Biotechs earnings growth	25.1%
Revenue growth rate	76.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	23 Jun 2026

Recent future growth updates

Recent updates

Analysis Article • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Feb 06

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Summary Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. CRBP expects to initiate a registrational CRB-701 study in mid-2026 and release 12-week CRB-913 obesity data in summer 2026. Early CRB-913 data show a 2.9% placebo-adjusted mean weight loss at Day 14 with a favorable safety profile and no nausea or vomiting. With $177.8M in cash post-raise, CRBP is funded into 2028, mitigating near-term dilution risk. Read the full article on Seeking Alpha

Analysis Article • Jul 07

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analysis Article • Mar 22

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analysis Article • Dec 06

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Corbus...

Seeking Alpha • Nov 11

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Summary Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway. Market concerns over CNS side effects from similar drugs may be overblown. CRB-913's design aims to avoid these issues, enhancing its blockbuster potential. CRB-913, a CB1 inverse agonist for obesity, aims to reduce CNS side effects and presents potential for combination therapy with GLP-1 agonists. Read the full article on Seeking Alpha

Seeking Alpha • Jan 30

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Summary Positive results released from phase 1 China study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive solid tumors. Trial initiation of phase 1 study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive tumors, expected in Q1 of 2024. Additional results from the phase 1 China study, using CRB-701 for the treatment of patients with nectin-4 positive solid tumors, expected at medical meetings throughout 2024. Another ADC, known as PADCEV, is expected to generate $5 billion in projected revenues in urothelial carcinoma. Read the full article on Seeking Alpha

Seeking Alpha • Aug 09

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q2 GAAP EPS of -$0.11. As of June 30, 2022, the Company has $74 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.

Earnings and Revenue Growth Forecasts

NasdaqCM:CRBP - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2028	3	-164	-144	-147	9
12/31/2027	2	-123	-107	-103	9
12/31/2026	1	-98	-96	-68	9
3/31/2026	N/A	-85	-74	-74	N/A
12/31/2025	N/A	-79	-64	-64	N/A
9/30/2025	N/A	-68	-60	-60	N/A
6/30/2025	N/A	-58	-58	-58	N/A
3/31/2025	N/A	-50	-50	-50	N/A
12/31/2024	N/A	-40	-42	-42	N/A
9/30/2024	N/A	-39	-37	-37	N/A
6/30/2024	N/A	-35	-30	-30	N/A
3/31/2024	N/A	-34	-29	-29	N/A
12/31/2023	N/A	-45	-36	-36	N/A
9/30/2023	N/A	-47	-38	-38	N/A
6/30/2023	N/A	-46	-38	-38	N/A
3/31/2023	N/A	-51	-42	-42	N/A
12/31/2022	N/A	-42	-38	-38	N/A
9/30/2022	N/A	-42	-40	-40	N/A
6/30/2022	0	-35	-32	-32	N/A
3/31/2022	0	-39	-37	-37	N/A
12/31/2021	1	-46	-48	-48	N/A
9/30/2021	2	-44	-57	-57	N/A
6/30/2021	3	-77	-85	-85	N/A
3/31/2021	3	-98	-94	-94	N/A
12/31/2020	4	-111	-100	-100	N/A
9/30/2020	6	-129	-106	-104	N/A
6/30/2020	7	-115	-97	-94	N/A
3/31/2020	36	-75	-87	-84	N/A
12/31/2019	36	-71	N/A	-46	N/A
9/30/2019	35	-62	N/A	-37	N/A
6/30/2019	34	-56	N/A	-29	N/A
3/31/2019	6	-70	N/A	-18	N/A
12/31/2018	5	-56	N/A	-30	N/A
9/30/2018	3	-49	N/A	-25	N/A
6/30/2018	3	-41	N/A	-23	N/A
3/31/2018	2	-37	N/A	-23	N/A
12/31/2017	2	-32	N/A	-28	N/A
9/30/2017	3	-29	N/A	-24	N/A
6/30/2017	3	-28	N/A	-21	N/A
3/31/2017	3	-25	N/A	-18	N/A
12/31/2016	2	-20	N/A	-14	N/A
9/30/2016	2	-15	N/A	-9	N/A
6/30/2016	1	-12	N/A	-8	N/A
3/31/2016	1	-10	N/A	-6	N/A
12/31/2015	1	-9	N/A	-5	N/A
9/30/2015	0	-8	N/A	-5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRBP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CRBP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CRBP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CRBP's revenue (76.7% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: CRBP's revenue (76.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CRBP's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/06 22:03
End of Day Share Price	2026/07/06 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Corbus Pharmaceuticals Holdings, Inc. is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Kalpit Patel	B. Riley Securities, Inc.
Mayank Mamtani	B. Riley Securities, Inc.
George Zavoico	B. Riley Securities, Inc.

Corbus Pharmaceuticals Holdings Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 7.4% to US$39.00

Price target increased by 8.2% to US$44.00

Price target decreased by 7.2% to US$42.89

Consensus EPS estimates upgraded to US$4.32 loss

Price target decreased by 9.9% to US$56.78

Price target decreased by 13% to US$71.00

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Reports Updated Clinical Data For CRB-701 Phase 1/2 Study In Oropharyngeal And Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. Appoints Nishant Saxena as Chief Business Officer

New minor risk - Share price stability

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

Corbus Pharmaceuticals Holdings Announces Updated Clinical Data From Phase 1/2 Study Of CRB-701 And Provides Update On CANYON-1 Phase 1b Study Of CRB-913

Price target decreased by 7.4% to US$39.00

Corbus Pharmaceuticals Holdings, Inc. Announces Updated Clinical Data for CRB-701 At ASCO 2026

Corbus Pharmaceuticals Holdings, Inc. Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Chief Medical Officer Dr. Dominic Smethurst, Effective June 30, 2026

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 13, 2026

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Alan Holmer from its Board of Directors, Effective December 31, 2025

Corbus Pharmaceuticals Holdings, Inc. Reports Results from Phase 1A Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

New major risk - Shareholder dilution

Price target increased by 8.2% to US$44.00

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $74.999901 million.

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc. Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals Holdings Inc. to Present CRB-701 Phase 1/2 Data At ESMO 2025

Corbus Pharmaceuticals Holdings, Inc. to Host In-Person and Virtual KOL Event At ESMO 2025

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB -701 in Head and Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for Its Nectin-4 Targeting Adc CRB -701 At the 2025 ESMO Annual Congress

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Corbus Pharmaceuticals Holdings Inc. Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) dropped from Russell 3000E Value Index

Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed with Its Nectin-4 Targeting ADC CRB-701 in Combination with Keytruda (Pembrolizumab)

Price target decreased by 7.2% to US$42.89

Corbus Pharmaceuticals Holdings, Inc. Announces Board Changes, Effective May 15, 2025

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 15, 2025

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

Peter Salzmann Not to Stand for Re-Election as Director of Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Appoints Ian Hodgson as Chief Operating Officer

Consensus EPS estimates upgraded to US$4.32 loss

New minor risk - Market cap size

CEO & Director notifies of intention to sell stock

New minor risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Presents Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701

Corbus Pharmaceuticals Holdings, Inc. Announces Clinical Data for CRB-701 from Western Dose Escalation Study to Be Presented at ASCO GU 2025

Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment

Price target decreased by 9.9% to US$56.78

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Price target decreased by 13% to US$71.00

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering.

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Corbus Pharmaceuticals Holdings, Inc. Announces Data from the First-in-Human Clinical Study of CRB-701 (SYS6002)

Nasdaq Gants Corbus Pharmaceuticals Holdings an Extension Until May 8, 2024 to Regain Compliance

Corbus Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement for Continued Listing on The Nasdaq Capital Market, Under Listing Rule 5550(b)(1)